Gossamer Bio (GOSS) Stock Forecast, Price Target & Predictions
GOSS Stock Forecast
Gossamer Bio stock forecast is as follows: an average price target of $3.75 (represents a 464.25% upside from GOSS’s last price of $0.66) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.
GOSS Price Target
The average price target for Gossamer Bio (GOSS) is $3.75 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $2.00. This represents a potential 464.25% upside from GOSS's last price of $0.66.
GOSS Analyst Ratings
According to 12 Wall Street analysts, Gossamer Bio's rating consensus is 'Buy'. The analyst rating breakdown for GOSS stock is 0 'Strong Buy' (0.00%), 8 'Buy' (66.67%), 4 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Gossamer Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 08, 2022 | - | H.C. Wainwright | $5.00 | $2.16 | 131.48% | 652.33% |
| Dec 07, 2022 | - | Barclays | $2.00 | $2.36 | -15.25% | 200.93% |
| Dec 07, 2022 | - | Raymond James | $5.00 | $2.36 | 111.86% | 652.33% |
| Dec 06, 2022 | David Hoang | SMBC Nikko | $3.00 | $2.36 | 27.12% | 351.40% |
| Apr 26, 2022 | - | Barclays | $12.00 | $8.45 | 42.01% | 1705.60% |
| Apr 26, 2022 | - | Raymond James | $10.00 | $9.08 | 10.13% | 1404.66% |
The latest Gossamer Bio stock forecast, released on Dec 08, 2022 by H.C. Wainwright company, set a price target of $5.00, which represents a 131.48% increase from the stock price at the time of the forecast ($2.16), and a 652.33% increase from GOSS last price ($0.66).
Gossamer Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.66 | $0.66 | $0.66 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Gossamer Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Gossamer Bio's last price of $0.66. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 24, 2024 | Oppenheimer | Buy | Outperform | Initialise |
| May 06, 2024 | Guggenheim | - | Positive | Initialise |
| May 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 06, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Mar 07, 2023 | Raymond James | Outperform | Market Perform | Downgrade |
| Dec 08, 2022 | Oppenheimer | Buy | Buy | Hold |
| Dec 07, 2022 | Goldman Sachs | Buy | Buy | Hold |
| Dec 07, 2022 | UBS | Buy | Buy | Hold |
Gossamer Bio's last stock rating was published by H.C. Wainwright on Sep 18, 2024. The company gave GOSS a "Buy" rating, the same as its previous rate.
Gossamer Bio Financial Forecast
Gossamer Bio Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $23.71M | $10.00M | $9.48M | $9.48M | $10.47M | $3.56M | $3.56M | $3.56M | $7.02M | $8.53M | $114.29M |
| High Forecast | $46.73M | $19.70M | $18.68M | $18.68M | $20.64M | $7.01M | $7.01M | $7.01M | $18.18M | $16.81M | $114.29M |
| Low Forecast | $11.19M | $4.72M | $4.47M | $4.47M | $4.94M | $1.68M | $1.68M | $1.68M | $949.04K | $4.03M | $114.29M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Gossamer Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. GOSS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Gossamer Bio EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict GOSS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Gossamer Bio's previous annual EBITDA (undefined) of $NaN.
Gossamer Bio Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-21.39M | $-31.59M | $-39.52M | $-39.54M | $-33.57M | $-40.49M | $-40.63M | $-42.03M | $-37.66M | $-33.31M | $114.68M |
| High Forecast | $-6.71M | $-9.90M | $-12.39M | $-12.40M | $-10.53M | $-12.70M | $-12.74M | $-33.18M | $-17.72M | $-10.44M | $114.72M |
| Low Forecast | $-48.37M | $-71.43M | $-89.38M | $-89.43M | $-75.91M | $-91.58M | $-91.89M | $-48.66M | $-46.52M | $-75.33M | $114.64M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Gossamer Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GOSS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Gossamer Bio SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Gossamer Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to GOSS last annual SG&A of $NaN (undefined).
Gossamer Bio EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.09 | $-0.14 | $-0.17 | $-0.17 | $-0.15 | $-0.18 | $-0.18 | $-0.19 | $-0.17 | $-0.15 | $0.51 |
| High Forecast | $-0.03 | $-0.04 | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.06 | $-0.15 | $-0.08 | $-0.05 | $0.51 |
| Low Forecast | $-0.21 | $-0.32 | $-0.39 | $-0.40 | $-0.34 | $-0.40 | $-0.41 | $-0.21 | $-0.21 | $-0.33 | $0.51 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Gossamer Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GOSS previous annual EPS of $NaN (undefined).
Gossamer Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.54 | $6.00 | 1011.11% | Buy |
| XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
| BDTX | Black Diamond Therapeutics | $2.43 | $14.75 | 507.00% | Buy |
| GOSS | Gossamer Bio | $0.66 | $3.75 | 468.18% | Buy |
| INZY | Inozyme Pharma | $2.69 | $14.67 | 445.35% | Buy |
| FDMT | 4D Molecular Therapeutics | $7.99 | $41.00 | 413.14% | Buy |
| BMEA | Biomea Fusion | $6.38 | $22.75 | 256.58% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.31 | $7.00 | 203.03% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| STOK | Stoke Therapeutics | $11.27 | $30.60 | 171.52% | Buy |
| TERN | Terns Pharmaceuticals | $5.71 | $14.25 | 149.56% | Buy |
| REPL | Replimune Group | $11.05 | $24.20 | 119.00% | Buy |
| KRON | Kronos Bio | $0.87 | $1.63 | 87.36% | Buy |
| AKRO | Akero Therapeutics | $31.20 | $46.00 | 47.44% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.19 | $6.67 | 28.52% | Buy |
| ALEC | Alector | $3.76 | $4.00 | 6.38% | Buy |